Renault Group has announced a minority investment in Wandercraft, which claims to be the first company to develop, manufacture and market medical self-balancing exoskeletons. Wandercraft has developed a new platform for manufacturing applications.
Through a commercial partnership agreement, Renault Group and Wandercraft will further develop Calvin, a family of next generation robots for industrial uses.
Calvin could allow Renault Group to relieve workers from painful and non-ergonomic tasks, while reducing production time. At a later stage, the partnership will also include the industrialization of robots and exoskeletons by Renault Group in order to reduce costs through design-to-cost and scaling. This will help Wandercraft bring its new exoskeleton, Eve, to market and open new business opportunities.
Thierry Charvet, Chief Industry and Quality Officer of Renault Group, said, "This partnership with Wandercraft is a forward-looking move. It will allow us to accelerate on automation and to develop robots for our specific auto industrial use, giving us the opportunity to concentrate our people on more value-adding tasks and alleviate operators from painful and non-ergonomics duties. It will drive productivity through the acceleration of production time and costs’ reduction."
